A recent study published in JAMA Network Open explored the experiences of 30 adults using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight management. Conducted across 15 US states, the research revealed that while these medications significantly reduce psychological cravings for food, they are not miracle cures. Participants noted that the drugs helped them regain control over their eating behaviors, but emphasized the importance of supporting lifestyle changes such as improved diet and increased physical activity. Many reported side effects ranging from mild nausea to severe gastrointestinal issues, with some finding discomfort a reminder of fullness. Stigma associated with weight-loss medications led some to frame their use as diabetes treatment to avoid judgment. Additionally, affordability and insurance coverage emerged as significant barriers to access. The findings underscore the need for comprehensive patient education, ongoing healthcare provider support, and equitable access to treatment, highlighting that GLP-1 RAs should complement, not replace, personal effort in weight management.